National Pediculosis Association launches head lice info campaign
NEWTON, Mass. The National Pediculosis Association on Thursday launched its 2009-2010 back-to-school campaign “Precaution, Preparedness & Peace of Mind” to equip parents, teachers and children with educational resources around treating lice.
“We must empower everyone with clear and up-to-date information so they make informed decisions,” stated Deborah Altschuler, president and co-founder of the NPA. “There is no need to panic and subject children to harmful chemicals with life-threatening side effects.”
As part of its campaign, NPA promotes routine screening, early detection and thorough removal of head lice and nits without the use of harmful chemicals or pesticides.
“For most of us the thought of pesticides on our fruits and vegetables is unacceptable. Yet, putting pesticides on our children has become acceptable. This makes no sense,” Altschuler said. “We want parents to know they have options, feel confident about their decisions, and be careful about the information they take off of the Internet.”
Study: Birth control pill use may decreases risk of urinary incontinence
WASHINGTON A new study from Sweden published Wednesday found that users of oral contraception have significantly reduced rates of urinary incontinence compared with women who used other forms of contraception.
Researchers at the Karoliska Institute and at Gothenburg University used the Swedish Twin Registry to examine the relationship between the use of oral contraceptives and urinary incontinence. After using statistical methods to control for factors such as age, Body Mass Index and ever having been pregnant, the data showed that the women who had used oral contraceptives had lower rates of lower urinary tract symptoms than non-users.
“With so many women using oral contraceptives, it is vital that we continue to fully understand their non-contraceptive effects, both positive and negative,” stated Dale McClure, president of the American Society for Reproductive Medicine. “This kind of research will help us better advise our patients as they make decisions about contraception, or possibly seek to avoid urinary tract problems.”
Amgen releases results of bone loss trial
THOUSAND OAKS, Calif. Amgen on Tuesday announced the publication of results from two pivotal phase 3 studies investigating the safety and effectiveness of denosumab at reducing fracture risk in more than 7,800 women with postmenopausal osteoporosis and in more than 1,400 men with nonmetastatic prostate cancer undergoing androgen deprivation therapy leading to bone loss.
In both studies, published Aug. 11 in The New England Journal of Medicine, patients receiving twice-yearly denosumab experienced significant increases in bone mineral density compared with placebo, associated with more than 60% reduction in vertebral fracture in both patient populations.
“The discovery of the RANK Ligand pathway represents a significant advance in the understanding of bone biology,” stated Roland Baron, professor and chair of department of Oral Medicine, Infection and Immunity at the Harvard School of Dental Medicine. “These results demonstrate that targeting the RANK Ligand pathway with denosumab could represent a promising new approach in two different disease settings characterized by bone loss.”